vaccine-safety
Does a COVID mRNA booster raise myocarditis risk?
Open access · cc by · source: Europe PMC
In England, myocarditis admissions rose mainly in males 16–39 within 0–6 days after mRNA doses (highest after dose 2); boosters still elevated risk but prior infection lowered vaccine-associated RIs.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Inspect source passages
Does a COVID mRNA booster raise myocarditis risk?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
2,284 myocarditis and 1,651 pericarditis admissions in the study period.
There were 2,284 admissions for myocarditis and 1,651 for pericarditis in the study period.
ChAdOx1-S first-dose RI 5.23 (95% CI 2.48–11.01).
For ChAdOx1-S, an elevated RI was only observed after a first dose, RI 5.23 (95% CI [2.48, 11.01]; p < 0.001).
Key findings
2,284 myocarditis and 1,651 pericarditis admissions. Elevated vaccine RIs mainly in 16–39-year-olds 0–6 days post-dose, especially males. ChAdOx1-S elevation only after first dose (RI 5.23). Prior infection lowered second-dose RIs; infection itself raised risk over 1–27 days.
Methodology
Ran a nationwide self-controlled case series comparing admission risk windows after BNT162b2, mRNA-1273, and ChAdOx1-S doses and after SARS-CoV-2 infection, stratified by age, sex, dose, and prior infection.
Limitations
Hospital-admission SCCS estimates rare absolute risks incompletely for mild outpatient cases; does not weigh COVID benefits vs risks for individuals.
Related papers in this topic
Same topic cluster — not a recommendation engine.